Press ReleasesAnnouncements
-
Dr. Reddy’s Q3 FY10 Financial Results: Revenues at Rs. 17,296 million;
EBITDA at Rs. 3,666 million, Profits after Tax adjusted for impairment at Rs. 2,307 million
January 20, 2010 -
Dr. Reddy's to release Q3 FY10 results on Jan 20, 2010
Earnings call slated for Jan 20, 6.30 PM IST / 8.00 AM EST
January 11, 2010 -
Dr. Reddy's and Rheoscience announce headline results from First Phase III clinical trial of Balaglitazone (DRF 2593)
January 4, 2010
- Dr. Reddy’s announces the Launch of Tacrolimus Capsules, the generic version of Prograf®
May 21 , 2010 - Dr. Reddy’s FY10 Financial Results, Revenues at Rs. 70.3 billion ($1.56 billion), EBITDA Adjusted* at Rs. 15.8 billion ($352 million), Profits after Tax Adjusted* at Rs. 9.2 billion ($205 million)
May 6 , 2010 - Dr. Reddy's to release Q4 & Full Year FY10 results on May 6, 2010
Earnings call slated for May 6, 6.30 PM IST / 9.00 AM EST
May 3, 2010
- Dr. Reddy’s Q1 FY11 Financial Results: Revenue at Rs. 16.8 billion ($363 million);
EBITDA at Rs. 3.4 billion ($74 million); Profit after Tax at Rs. 2.1 billion ($45 million)
July 22 , 2010 - Dr. Reddy's to release Q1 FY11 results on July 22, 2010
Earnings call slated for July 22, 6.30 PM IST / 9.00 AM EST
July 9 , 2010
- Dr. Reddy's expands portfolio in Russia & CIS through in-licensing deals.
October 25, 2010 - Dr. Reddy's Q2 FY11 Financial Results: Revenue at Rs. 18.7 billion ($420 million); (Growth » 2% YoY & 11% QoQ)
EBITDA at Rs. 4.2 billion ($95 million); (Growth » 12% YoY & 24% QoQ)
Profit after Tax at Rs. 2.9 billion ($64 million); (Growth » 32% YoY & 37% QoQ)
October 23, 2010 - Dr. Reddy's announces the approval of Lansoprazole delayed-release capsules
October 19, 2010 - Dr. Reddy's to release Q2 FY11 results on October 23, 2010; Earnings call slated for October 23, 5:00 PM IST / 7.30 AM EST
October 12, 2010
- GlaxoSmithKline and Dr. Reddy’s agree to the sale of US Penicillin Facility and Products
November 23, 2010 - Dr. Reddy’s announces the Launch of Zafirlukast Tablets
November 20, 2010
- Dr. Reddy’s Q3 FY09 Revenue at Rs. 18,401 million,EBITDA at Rs. 3,453 million, PAT at Rs. 1,924 million
January 20 , 2009 -
Dr. Reddy's to release Q3 FY09 results on January 20, 2009;Earnings call slated for January 20, 6.30 PM IST/8.00 AM EST
January 9 , 2009 -
Dr. Reddy’s announces the appointment of new Chief Financial Officer (CFO)
January 2 , 2009
-
Dr. Reddy’s launches Nexret™
April 28, 2009 -
Dr. Reddy’s launches ‘Redispar™’ in India
April 22, 2009 -
Dr. Reddy’s Laboratories realigns Global Generics geography portfolio
March 19, 2009
-
Dr. Reddy’s receives approval for Three INDs and announces reorganization of its
Drug Discovery Operations
May 21, 2009 -
Dr. Reddy’s FY09 Revenues at Rs. 69,441 million,
EBITDA at Rs. 14,505 million
May 18, 2009 -
Dr. Reddy's to release FY09 results on May 18, 2009;
Earnings call slated for May 18, 6.30 PM IST / 9.00 AM EST
May 6, 2009
- Dr. Reddy’s launches Bispec™ in India
June 23, 2009 -
Dr. Reddy’s announces strategic alliance with GSK for Emerging Markets
June 15, 2009 -
Dr. Reddy’s announces ANDA approval of Omeprazole Mg OTC
June 9, 2009
- Dr. Reddy’s launches Execare™ in India
July 30, 2009 - Promius Pharma Launches Promiseb™ Cream
July 29, 2009 - Dr. Reddy’s Q1 FY10: Revenues at Rs. 18,189 million, up by 21%;
EBITDA at Rs. 4,364 million, up by 90%; PAT at Rs. 2,445 million, up by 120%
July 21, 2009 - Dr. Reddy’s to release Q1 FY10 results on Jul 21, 2009;
Earnings call slated for Jul 21, 6.30 PM IST / 9.00 AM EST
July 9, 2009 - Dr. Reddy’s Laboratories Limited announces filing of Annual Report on Form 20-F
July 7, 2009
- Dr. Reddy’s launches Strea™ Professional in India
August 13, 2009 - Dr. Reddy’s launches FINRID™ in India
August 5, 2009
- Dr. Reddy’s joins American Chemical Society Green Chemistry Institute® Pharmaceutical Roundtable
October 20, 2009 - Dr. Reddy's to release Q2 FY10 results on Oct 23, 2009;
Earnings call slated for Oct 23, 6.00 PM IST / 8.30 AM EST
October 12, 2009 - Dr. Reddy’s launches Strea™ C10 and Strea™ A15 in India
October 6, 2009
-
Dr. Reddy’s launches authorized generic version of Imitrex®* Tablets
November 24, 2008
-
Dr. Reddy’s Q2 FY09 Revenue at Rs. 16,151 million,EBITDA at Rs. 2,746 million, PAT at Rs. 1,212 million
October 23, 2008 -
Dr. Reddy’s wholly-owned subsidiary Promius Pharma launches EPICERAM® skin barrier emulsion
October 14, 2008 -
Dr. Reddy's to release Q2 FY09 results on October 23, 2008;Earnings call slated for October 23, 6.30 PM IST/9.00 AM EST
October 13, 2008
-
Dr. Reddy’s enters the respiratory inhalers market in India with the launch of ‘Combihale™’ and ‘Redihaler™’.
September 25, 2008 -
Dr. Reddy’s formally announces its US Specialty Business, Promius Pharma, LLC.
September 18, 2008 -
Dr. Reddy’s announces partnership with Cosmederm Technologies for Indian distribution of proprietary skin care products
September 4, 2008
-
Dr. Reddy’s Laboratories Limited invests in Perlecan Pharma Private Limited by acquiring shares of Joint Venture Partners .
July 30, 2008 -
Dr. Reddy’s Q1 FY09 Revenue at Rs. 15,038 million;EBITDA at Rs. 2,710 million, PAT at Rs. 1,346 million.
July 21, 2008 -
Dr. Reddy's Annual Report on FORM 20-F for year ended march 31, 2008 available on the company's website
July 18, 2008 -
Dr. Reddy's to release Q1 FY09 results on July 21, 2008; Earnings call slated for July 21, 6.30 PM IST/9.00 AM EST
July 15, 2008 -
Dr. Reddy’s signs global distribution agreement with Albemarle Corporation for Ibuprofen API
July 08, 2008
-
Dr Reddy’s launches ‘Atocor-R’ – combination of Atorvastatin and Ramipril in India.
May 29, 2008 -
Dr. Reddy’s launches ‘Omez Insta’ – Immediate Release Omeprazole in sachets
May 22, 2008 -
Dr. Reddy’s FY08 Revenue at Rs. 50,006 million;EBITDA at Rs. 9,736 million;
May 20, 2008 -
Dr. Reddy's to release FY08 results on May 20, 2008;Earnings call slated for May 20, 6.30 PM IST/9.00 AM EST
May 12, 2008 -
Dr. Reddy’s announces the completion of two acquisitions
May 01, 2008
-
Dr. Reddy’s Acquires BASF’s Pharmaceutical Contract Manufacturing Business and related facility at Shreveport in the US
April 30, 2008 -
Dr. Reddy’s acquires Jet Generici Srl.Acquisition to establish Generics business in Italy.
April 03, 2008 -
Dr. Reddy’s signs definitive agreement to acquire Dowpharma Small Molecules business associated with Dow’s Mirfield and Cambridge, UK Sites
April 01, 2008
-
Dr. Reddy’s Q3 FY08 Revenue at Rs 12,320 million;EBITDA at Rs 2,037 million
January 25, 2008 -
Dr. Reddy’s announces settlement of Exelon® (rivastigmine tartrate) ANDA litigation with Novartis
January 21, 2008 -
Dr. Reddy's to release Q3FY08 results on January 25, 2008; Earnings call slated for January 25, 6.30 PM IST/8.00 AM EST
January 18, 2008 -
Dr. Reddy's launches Supanac® - (Diclofenac potassium)
January 16, 2008
-
Dr. Reddy's Annual Report on Form 20-F for year ended March 31, 2007 available on the company's website
September 28, 2007 -
Dr. Reddy's commences operations in Philippines. Expands presence in the ASEAN region
September 28, 2007 -
Dr. Reddy's receives USFDA approval for Ranitidine (Zantac™) Tablets, 150mg (OTC)
September 13, 2007 -
Dr. Reddy's enters the Dermatology topical anti-fungal market with the launch of ‘EbernetTM’ - (Eberconazole)
September 05, 2007
-
Dr. Reddy’s Q1 FY08 revenue at Rs 12,018 million;
Net income at Rs 1,825 million;
July 23, 2007 -
Dr. Reddy's to release Q1 FY08 results on July 23, 2007; Earnings call slated for July 23, 6.30 PM IST/9.00 AM EST
July 18, 2007 -
Dr. Reddy's launches Glimy MP 1 and Glimy MP2. Triple drug combination ideal to address the triple defects in diabetes
July 10, 2007
-
Dr. Reddy’s announces new R&D Chief
April 30, 2007 -
Dr. Reddy's launches Reditux™ - Monoclonal Antibody Treatment for Non-Hodgkin's Lymphoma
April 30, 2007 -
Dr. Reddy's announces the launch of Zolpidem Tartrate tablets
April 25, 2007 -
Dr. Reddy's employees awarded PG certificates from BITS Pilani
April 24, 2007 -
Dr. Reddy's is the First Participant in United States Pharmacopoeia's New Pharmaceutical Ingredient Verification Programme
April 17, 2007
-
Dr. Reddy's Announces Final Approval of Ondansetron Tablets with 180 Days of Marketing Exclusivity
December 27, 2006 -
Perlecan Pharma moves Dr. Reddy's novel anti-diabetic drug candidate to Phase I clinical trial
December 26, 2006 -
Dr. Reddy's Teams Up With University of Aukland for World's First Polypill Trial
December 7, 2006
-
Dr. Reddy's Announces Issuance of Additional American Depositary Shares
November 29, 2006 -
Dr. Reddy’s and Torrent Pharma Sign Agreement For Exclusive Commercialization Of Listril And Listril Plus In Russia
November 29, 2006 -
Dr. Reddy's announces pricing of American Depository Shares
November 16, 2006 -
Dr. Reddy's files F-3 registration statement with the U.S. Securities and exchange commission
November 13, 2006
-
Top Management Moves at Dr. Reddy's
June 28, 2006 -
Dr. Reddy’s launches authorized generic versions of Proscar® and Zocor®
June 23, 2006
-
Dr. Reddy's FY06 revenue at Rs. 24,267 million;
Net income at Rs. 1,629 million;
May 31, 2006 -
Dr. Reddy's to release FY06 results May 31, 2006;
Earnings call slated for May 31, 6.30 PM IST/9.00 AM EST
May 24, 2006 -
Dr Reddy's launches 'Doxobid' - a new oral bronchodilator for asthma & COPD
May 15, 2006
-
Dr. Reddy's completes the acquisition of betapharm
March 04, 2006
-
Dr. Reddy's signs definitive agreement with 3i for the strategic acquisition of betapharm
February 16, 2006 -
Dr.Reddy's and Argenta Discovery announce R&D collaboration
February 02, 2006
-
Dr. Reddy’s reports Q2 FY06 revenue of Rs. 5,803 million;
YoY growth of 7% Net income increases by 72% to Rs. 890 million
October 29, 2005 -
Dr. Reddy's launches ‘Viboliv’ - (Metadoxine) to enter the hepatoprotectives market
October 17, 2005 -
Dr. Reddy's is IBLA - Indian Corporate Citizen of the Year - 2005
October 03, 2005
-
Dr. Reddy's launches ‘Shadowz' a unique high SPF protection sunscreen
August 25, 2005 -
Dr. Reddy’s & NMIMS Partner on a unique MBA program
August 08, 2005
-
Dr. Reddy’s records Q1 FY06 revenue growth of 9% to Rs. 5,587
million
Net income increases to Rs. 347 million from Rs. 173 million in Q1 FY05
July 26, 2005 -
Dr. Reddy's to release Q1 FY06 results July 26, 2005; Earnings call slated for July 26, 6.30 PM IST/9.00 AM EST
July 20, 2005 -
Dr. Reddy’s organizes an International Symposium on Gastro Intestinal Cancer
July 15, 2005 -
Dr. Reddy's launches a novel immune booster for children Product launched in collaboration with Symbiotics of New Zealand
July 14, 2005
-
Dr. Reddy's announces USFDA approval for Citalopram Hydrobromide tablets
October 29, 2004 -
Novo Nordisk terminates further clinical development of Balaglitazone (DRF 2593) out-licensed by Dr. Reddy's
October 27, 2004 -
Dr. Reddy's Q2 FY05 revenue at Rs.5,407 million; Net income at Rs.517 million
October 26, 2004 -
Dr. Reddy's Announces Litigation on ANDA for Finasteride tablets 1 mg
October 1, 2004
-
Dr. Reddy's Employees Awarded Msc. in Pharmaceutical Chemistry by BITS Pilani
September 13, 2004 -
Dr. Reddy's Announces Termination of Lamisil® Litigation
September 3, 2004
-
Dr. Reddy's launches cream for treating dry skin conditions.
August 12, 2004
-
Dr. Reddy's FY04 revenue at Rs. 20,081 million; Net income at Rs. 2,474 million
May 28, 2004 -
Dr. Reddy's wins prestigious WorldStar award for Omez ® pack from World Packaging Organization.
May 14, 2004 -
Dr. Reddy's acquires access to Drug Delivery Technology Platforms in the Dermatology Segment Marks Company's foray into the $6 billion niche dermatology segment in the US
May 6, 2004 -
Dr. Reddy's moves into the heart of the U.S. Pharmaceutical Industry
May 3, 2004
-
Dr. Reddy's Laboratories Announces Appeals Court Ruling On Amlodipine Maleate
February 27, 2004 -
Dr. Reddy's confirms ANDA filing for Amlodipine Besylate tablets
February 24, 2004 -
Dr. Reddy's signs definitive agreement for sale of Compact Electric Limited
February 9, 2004 -
Dr. Reddy's receives FDA letter on AmVazTM (Amlodipine)
February 7, 2004
-
Dr. Reddy's Q3 FY04 revenue at Rs.5138 million; Net income at Rs.592 million
January 30, 2004 -
Dr. Reddy's appoints Dr. Dennis Langer President, North America
January 20, 2004 -
Dr. Reddy's organizes international symposium on drug discovery to commemorate ten years of Dr. Reddy's drug discovery research
January 16, 2004
-
Dr. Reddy's announces ANDA filing for Sumatriptan Succinate oral tablets
December 31, 2003
-
Dr. Reddy's Announces ANDA Filing for Rabeprazole Sodium
November 20, 2003 -
Dr. Reddy's - South African subsidiary
November 7, 2003 -
Dr. Reddy's Laboratories to present at American Heart Association Scientific Sessions
November 6, 2003 -
Dr. Reddy's receives final approval for AmVazTM (Amlodipine Maleate)
November 3, 2003
-
Dr. Reddy's announces USFDA approval for Nefazodone HCL tablets
September 17, 2003 -
Dr. Reddy's Safety, Health and Environment Annual Report - Released
September 16, 2003 -
Dr. Reddy's announces ANDA filing for Rosiglitazone Maleate
September 9, 2003
-
Dr. Reddy's announces ANDA filing for Fexofenadine HCl Tablets
March 26, 2003 -
Dr. Reddy's announces ANDA filing for Olanzapine ODT
March 11, 2003
-
Dr. Reddy's Laboratories and Leiner Health Products sign exclusive 15-year OTC product development and marketing agreement; Dr. Reddy's CEO to join Leiner's Board of Directors
February 24, 2003 -
Dr. Reddy's files lawsuit against Pfizer regarding Sertraline ANDA
February 24, 2003 -
Novo Nordisk to move forward on development of Dr. Reddy's Balaglitazone (DRF 2593); Not to pursue further development of Ragaglitazar (DRF 2725)
February 6, 2003
-
Dr. Reddy’s provides update on the fexofenadine-pseudoephedrine 24 hour litigation
January 31, 2011 -
Dr. Reddy’s Q3 FY11 Financial Results: Revenues at Rs. 19.0 billion ($424 million), YoY growth of 10%; EBITDA at Rs. 4.0 billion ($90 million), YoY growth of 10%; Profit after Tax at Rs. 2.7 billion ($61 million), YoY adjusted growth of 19%*
January 25, 2011 -
Dr. Reddy’s announces the launch of Pantoprazole Sodium delayed-released tablets
January 20, 2011 -
Dr. Reddy's to release Q3 FY11 results on January 25, 2011
Earnings call slated for January 25, 6:30 PM IST / 8.00 AM EST
January 12, 2011
-
Dr. Reddy's to release Q4 & Full Year FY11 results on May 13, 2011
Earnings call slated for May 13, 6.30 PM IST / 9.00 AM EST
April 26, 2011 -
Dr. Reddy’s announces the launch of Over-the-Counter fexofenadine HCl tablets
April 14, 2011 -
Dr. Reddy’s expands its R&D centre in Cambridge, United Kingdom
April 11, 2011 -
Promius™ Pharma and Valeant form collaboration to market Cloderm® cream in the United States
April 01, 2011
-
Dr. Reddy’s Q4 FY11 & FY11 Financial Results: Q4 FY11 Revenues at Rs. 20.2 billion ($453 million), YoY growth of 23%;Q4 FY11 Adjusted* Profit after Tax at Rs. 3.1 billion ($69 million), YoY growth of 57%;FY11 Revenues at Rs. 74.7 billion ($1.7 billion), YoY growth of 6%;FY11 Adjusted* Profit after Tax at Rs. 10.8 billion ($242 million), YoY growth of 17%
May 13, 2011 -
Dr. Reddy’s launches pegfilgrastim in India under the brand name ‘Peg-grafeel™’
- The only affordable pegfilgrastim in India
May 10, 2011
- Teva and Dr. Reddy’s announce launch of generic Zyprexa® in the United States
October 25, 2011 -
Dr. Reddy’s Q2 FY12 Financial Results : Q2 FY12 Revenues at ₹22.7 billion ($462 million), YoY growth of 21%; Q2 FY12 Adjusted* EBITDA at ₹5.1 billion ($104 million), YoY growth of 20%; Q2 FY12 Adjusted** PAT at ₹3.1 billion ($63 million), YoY growth of 8%
October 25, 2011 -
Dr. Reddy's to release Q2 FY12 results on October 25, 2011
Earnings call slated for October 25, 6.30 PM IST / 9.00 AM EST
October 12, 2011
-
Dr. Reddy’s and JB Chemicals & Pharmaceuticals (JBCPL) terminate Rx business deal in Russia and other CIS
September 26, 2011 -
Dr. Reddy’s announces the Launch of Rivastigmine Tartrate Capsules
September 22, 2011 -
Dr. Reddy’s announces start of Phase II study with the CETP inhibitor, DRL-17822 in dyslipidemia patients
September 02, 2011
-
FUJIFILM and Dr. Reddy’s to establish an exclusive joint venture for developing, manufacturing and promoting generic drugs in Japan
July 28, 2011 -
Dr. Reddy’s announces the launch of Gemcitabine for Injection
July 27, 2011 -
Dr. Reddy’s acquires prescription business of JB Chemicals & Pharmaceuticals in Russia & other CIS markets
July 22, 2011 -
Dr. Reddy’s Laboratories Limited announces filing of Annual Report on Form 20-F
July 21, 2011 -
Dr. Reddy’s Q1 FY12 Financial Results: Q1 FY12 Revenues at Rs. 19.7 billion ($444 million), YoY growth of 18%; Q1 FY12 Adjusted* EBITDA at Rs.4.3 billion ($97 million), YoY growth of 27%;
Q1 FY12 Adjusted** PAT at Rs. 2.5 billion ($56 million), YoY growth of 20%
July 20, 2011 -
Dr. Reddy’s announces the USFDA Approval of Fondaparinux Sodium Injection
July 13, 2011 -
Dr. Reddy's to release Q1 FY12 results on July 20, 2011 Earnings call slated for July 20, 6.30 PM IST / 9.00 AM EST
July 7, 2011 -
Dr. Reddy’s announces the launch of Amlodipine Besylate and Benazepril Hydrochloride capsules
July 7, 2011
